Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

ODAN-VERNACON 0.5 % — DIN 00626643

PHENIRAMINE MALEATE : 0.5 % PHENYLEPHRINE HYDROCHLORIDE : 0.125 % · ODAN LABORATORIES LTD · SOLUTION · wholesale supply in Canada

Health Canada status: DORMANT

What is ODAN-VERNACON?

ODAN-VERNACON 0.5 % contains PHENIRAMINE MALEATE : 0.5 % PHENYLEPHRINE HYDROCHLORIDE : 0.125 %. It is listed in the Health Canada Drug Product Database under DIN 00626643, held by ODAN LABORATORIES LTD, supplied as SOLUTION for OPHTHALMIC administration. Health Canada currently lists it as dormant, status dated 22-Jun-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.

What is ODAN-VERNACON used for?

Prompt, effective relief from ophthalmic symptoms such as tearing, itching, redness and swelling in hay fever and other allergies.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Is there a generic Phenylephrine, Combinations in Canada, and who makes it?

Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.

5 holders have a Canadian DIN containing Phenylephrine, Combinations, across 7 DINs, of which 0 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.

Market authorization holderDINsMarketedBrand namesPosition
PHARMA STULLN INC.20DIOROUGE LIQ, PHENYLEPHRINE/HYDROXYETHYLCELLULOSENo marketed DIN
PRODUITS FRANCAIS LABS INC.20OCCU-CAL DROPS, OCCU-CAL LOTIONNo marketed DIN
ALCON CANADA INC10ZINCFRINNo marketed DIN
ALLERGAN INC10PREFRIN A LIQNo marketed DIN
ODAN LABORATORIES LTD10ODAN-VERNACONNo marketed DIN

Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.

How is it supplied and stored?

Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.

Strength on the label0.5 %
Dosage formSOLUTION
RouteOPHTHALMIC
Pack configuration (monograph)15 mL plastic dropper bottles.
StorageStore between 15 ºC and 30 ºC.

Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.

Substance and classification

Active substancePhenylephrine, Combinations
ATC codeS01GA55
AHFS class52:32.00 ; 04:04.20
Biosimilar biologicNo

Confirm the pack and get a price

Health Canada record and identifiers

The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.

DIN (8-digit, as used in ordering)00626643
DIN (unpadded, as printed on some documents)626643
Brand nameODAN-VERNACON
Generic / active ingredientPHENIRAMINE MALEATE : 0.5 % PHENYLEPHRINE HYDROCHLORIDE : 0.125 %
Market authorization holderODAN LABORATORIES LTD
Health Canada scheduleNON-PRESCRIPTION DRUGS
ATC codeS01GA55
ATC anatomical main groupS — Sensory organs
ATC therapeutic subgroupS01GA
Current statusDORMANT
Status date22-Jun-2017
Original market date1986-12-31 00:00:00
Status sourceLive Health Canada DPD sync

Verify on the primary sources

Health Canada DPD record Approved product monograph (PDF)

How is it administered?

One or two drops instilled into eye(s) every 3 to 4 hours.

Included because it drives pack selection and wastage. Consult the monograph.

Contraindications

Contraindicated in persons sensitive to any of its components.

Warnings and precautions

For topical ophthalmic use only. Caution if glaucoma suspected and in hypertensive or diabetic patients. Discontinue if sensitivity or irritation persists.

What can be used instead?

Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.

1 · Same molecule, other Canadian presentations

0 of 7 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.

ProductStrengthFormHolderHealth Canada statusDIN
DIOROUGE LIQ0.125 %SOLUTIONPHARMA STULLN INC.DORMANT02026511
OCCU-CAL DROPS1.9 MGDROPSPRODUITS FRANCAIS LABS INC.CANCELLED POST MARKET00540935
OCCU-CAL LOTION11.1 MGLOTIONPRODUITS FRANCAIS LABS INC.CANCELLED POST MARKET00540927
PHENYLEPHRINE/HYDROXYETHYLCELLULOSE0.5 %SOLUTIONPHARMA STULLN INC.DORMANT02026473
PREFRIN A LIQ.12 %LIQUIDALLERGAN INCCANCELLED POST MARKET00400408
ZINCFRIN.25 %LIQUIDALCON CANADA INCCANCELLED POST MARKET00042595

2 · Same class — other molecules in ATC S01GA

MoleculeCanadian brandsDINsMarketedSourceable
Tetryzoline, Combinations8-SYMPTOM RELIEF · ADVANCED RELIEF EYE DROPS · ALLERGY EYE DROPS · CLEAR EYES TRIPLE ACTION RELIEF · +11 more198Yes
Naphazoline, CombinationsALBALON A · ALLERGY EYE DROPS · BLUE COLLYRIUM · CLEAR EYES ACR BY MURINE · +16 more215Yes
NaphazolineALBALON · CLEAR EYES · CLEAR EYES BY MURINE EYE DPS · COLLYRE BLEU LAITER · +12 more162Yes
TetryzolineEYE DROPS · EYE DROPS 0.5MG/ML · ORIGINAL EYE DROPS · R.O.-EYE DROPS · +1 more62Yes
Phenylephrine, CombinationsDIOROUGE LIQ · OCCU-CAL DROPS · OCCU-CAL LOTION · ODAN-VERNACON · +3 more70Not in Canada
OxymetazolineCLARITIN EYE ALLERGY RELIEF · OCUCLEAR OPH DPS 0.025% · VISINE L.R. OPHTHALMIC SOL 0.025% · VISINE WORKPLACE40Not in Canada
PhenylephrinePREFRIN LIQ 0.12%10Not in Canada
Xylomethazoline, CombinationsOPHTRIVIN A OPHTHALMIC DPS10Not in Canada

A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.

3 · Adjacent classes in ATC S01G

ATC subgroupMoleculesDINsMarketed
S01GXCromoglicic Acid · Emedastine · Ketotifen · Levocabastine · Lodoxamide · +2 more3513

Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.

How can I get it?

This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.

Ask about sourcing ODAN-VERNACON

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Why is there no price on this page?

Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Sources and disclaimer

Product data sourced from the Health Canada Drug Product Database and the approved product monograph (PDF). Health Canada status reconciled against the live DPD sync. Last reviewed 10 Sep 2026.

Nothing on this page is medical advice. Nexara Health is a licensed wholesale distributor and supplies licensed entities only; consumer orders are routed to a partner pharmacy. Alternatives tables describe supply, not clinical equivalence.

Health Canada Drug Product Database (DPD), DIN 00626643. Last reviewed 2026-09-10. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.